PF-Atlas › Clinical Trials › NCT03928847

Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.

Epigallocatechin-3-gallate · Early Phase 1

Registry ID
NCT03928847
Phase
Early Phase 1
Status
Completed
Drug / intervention
Epigallocatechin-3-gallate (EGCG)
Sponsor
Hal Chapman
Start
2017-12-01
Enrollment
35
Locations
1

About this trial

This is a two part study. In the first part, the pharmacokinetic profile of Epigallocatechin-3-gallate (EGCG) in normal human volunteers given a single oral dose will be determined to set the dose for the second part of the study. In the second part of this study, lung biopsy fragments and urine samples from patients with interstitial lung disease treated with EGCG will be evaluated in biochemical assays and compared to samples from untreated control patients.

View NCT03928847 on ClinicalTrials.gov →

Explore related

All Epigallocatechin-3-gallate trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT03928847 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.